SCHEMBL6685327

SCHEMBL6685327

CC(C(=O)O)(C(=O)O)c1ccc(I)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.42
AKR1C3 P42330 3/20 0.41
AKR1C2 P52895 3/20 0.41
KCNN4 O15554 1/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
NR1H4 Q96RI1 3/20 0.33
EPHX2 P34913 2/20 0.33
PPARG P37231 1/20 0.32
GAA P10253 2/20 0.32
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
MAPT P10636 1/20 0.31
XBP1 P17861 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3711502 0.79 HDAC1 (0.42) APPAKR1C3AKR1C2KCNN4CYP3A4
SCHEMBL23070510 0.78 MMP8 (0.37) CYP3A4CYP1A2MAPK1HTT
SCHEMBL18596249 0.77 ALDH1A1 (0.41) GAACYP1A2CYP2D6MEN1NPC1
SCHEMBL3503786 0.76 APP (0.40) APPAKR1C3AKR1C2KCNN4CYP3A4
SCHEMBL10704177 0.75 APP (0.60) APPAKR1C3AKR1C2CYP3A4CYP2C9
SCHEMBL25168297 0.75 CNR2 (0.48) APPAKR1C3AKR1C2KCNN4CYP3A4
SCHEMBL29990602 0.75 CNR2 (0.48) APPAKR1C3AKR1C2KCNN4CYP3A4
SCHEMBL3714543 0.73 ATM (0.50) APPAKR1C3AKR1C2CYP3A4MEN1
SCHEMBL3714548 0.73 ATM (0.50) APPAKR1C3AKR1C2CYP3A4MEN1
SCHEMBL27609150 0.72 NPC1 (0.48) KCNN4HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004073705-A1 1-PHENYL-2- MONOALKYL CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CHIESI FARMACEUTICI S.P.A. (IT) 2004-09-02 WO disclosed